Skip to main content
Terug
Watch Compare

PROVECTUS BIOPHARMACEUTICALS, INC.

Datakwaliteit: 100%
PVCT
OTC Manufacturing Chemicals
€ 0,06
▲ € 0,00 (1,79%)
Marktkapitalisatie: 23,96 M
Prijs
€ 0,06
Marktkapitalisatie
23,96 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -3,33 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-45,54%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net Margin-1615,81%
Op. Margin-1575,32%

Veiligheid

Debt / Equity
N/A
Current Ratio0,04
Interest Coverage-991,90

Waardering

PE (TTM)
-4,41
Onder sectorgemiddelde (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -4,4 -1,5
P/B — 1,6
ROE % — -54,0
Net Margin % -1615,8 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42012 -€ 0,03 -€ 0,02 +33,3%
Q32012 -€ 0,03 -€ 0,02 +40,0%
Q22012 -€ 0,03 -€ 0,03 +10,0%
Q12012 -€ 0,04 -€ 0,04 -14,3%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -45,54% Revenue Growth (3Y) -22,37%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 336.108,0 Net Income (TTM) -5,43 M
ROE N/A ROA -950,87%
Gross Margin N/A Operating Margin -1575,32%
Net Margin -1615,81% Free Cash Flow (TTM) -3,33 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,04
Interest Coverage -991,90 Asset Turnover 0,59
Working Capital -6,19 M Tangible Book Value -6,15 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4,41 Forward P/E N/A
P/B Ratio N/A P/S Ratio 71,27
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -13,88%
Market Cap 23,96 M Enterprise Value 23,88 M
Per Share
EPS (Diluted TTM) -0,01 Revenue / Share 0,00
FCF / Share -0,01 OCF / Share -0,01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 61,24%
SBC-Adj. FCF -4,28 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 336.108,0 617.140,0 557.710,0 989.042,0 —
Net Income -5,43 M -4,73 M -3,10 M -3,55 M -5,54 M
EPS (Diluted) -0,01 -0,01 -0,01 — —
Gross Profit — — — — —
Operating Income -5,29 M -4,53 M -2,90 M -3,43 M -4,67 M
EBITDA — — — — —
R&D Expenses 1,90 M 2,00 M 1,75 M 2,39 M 2,61 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 5.338,0 13.591,0 5.650,0 -163.691,0 961.702,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 697.502,0 1,01 M 1,45 M 2,04 M 3,51 M
Total Liabilities 7,00 M 6,98 M 9,04 M 8,27 M 7,70 M
Shareholders' Equity -6,30 M -5,96 M -7,59 M -6,23 M -4,19 M
Total Debt — — — — —
Cash & Equivalents 251.291,0 307.442,0 76.576,0 21.605,0 682.984,0
Current Assets 567.874,0 976.772,0 1,36 M 1,90 M 3,44 M
Current Liabilities 6,90 M 6,98 M 9,02 M 8,19 M 7,70 M